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Introduction
During the last years spine surgery has witnessed a
trend towards increasing numbers of minimally invasive
procedures. Some of these, such as vertebroplasty (VP)
and kyphoplasty (KP), rely heavily on X-ray guidance
through ﬂuoroscopy or computed tomography (CT).
While the minimised soft tissue trauma and associated
co-morbidity is an unquestionable asset of these tech-
niques, the risk to the patient and the surgeon arising
from the considerable X-ray exposure during the pro-
cedure is not incompletely understood. Recent investi-
gations of the radiation exposure by surgeons and
operating room personnel during ﬂuoroscopy guided
vertebral augmentation have revealed relevant doses
that warrant speciﬁc safety measures such as whole
body aprons and lead collars besides technical reﬁne-
ments of the equipment and ﬂuoroscopes [6, 8, 9, 11,
14]. The relevance of the radiation exposure to the
patient, who necessarily receives the brunt of the dose
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Abstract Kyphoplasty (KP) is a
minimally invasive technique for the
percutaneous stabilisation of verte-
bral fractures. As such, this tech-
nique is highly dependent upon
intraoperative ﬂuoroscopic visuali-
sation. In order to assess the range
of radiation doses that patients are
typically subjected to, 60 consecutive
procedures using simultaneous
bilateral ﬂuoroscopy were analysed
with respect to exposure time (ET).
In a subset of 16 of these patients, a
theoretical entrance skin dose (ESD)
and eﬀective dose was additionally
calculated from intraoperatively
measured dose area product. Aver-
age ﬂuoroscopy time for single level
cases reached 2.2 min (range 0.6–
4.3) in the lateral plane and 1.6 min
(range 0.5–3.0) in the anterior–pos-
terior plane. For multiple level cases
the corresponding ET per level was
1.7 min (range 0.6–2.9) per level in
the lateral and 1.1 min (range 0.5–
2.0) in the anterior-posterior plane.
ESD was estimated as an average
0.32 Gy (range 0.05–0.86) in the
anterior–posterior and 0.68 Gy
(range 0.10–1.43) in the lateral
plane. Eﬀective dose (cumulative
from both planes) averaged
4.28 mSv (range 0.47–10.14). Safety
margins for the development of early
transient erythema are respected
within the presented ﬂuoroscopy
times. Longer ET in the lateral plane
may however breach the 2 Gy
threshold. Use of large c-arms and
judiciously operating the exposure is
recommended. With regard to eﬀec-
tive dose, a single ﬂuoroscopy gui-
ded KP performed for osteoporotic
or traumatic vertebral fractures is a
safe procedure.
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in VP and KP, has however only received limited
attention [12].
The purpose of this investigation was therefore to
analyse the biplanar ﬂuoroscopy exposure time (ET) of
KP patients and to estimate entrance skin dose (ESD)
and eﬀective dose (E) that the patient is typically sub-
jected to in order to provide a basis for radiation asso-
ciated risk assessment.
Materials and methods
Patient collective
Fifty-three successive patients (36 women, 17 men;
average age 73 years, range 49–90) treated for osteopo-
rotic or traumatic vertebral fractures through percuta-
neous KP were included in the investigation (Table 1).
Within a year of the initial KP procedure ﬁve patients
developed new fractures which were again treated with
KP in seven separate operative sessions. These proce-
dures were considered as separate cases for the purpose
of determining intraoperative radiation exposure.
Including these re-operations, 60 operative sessions were
evaluated in which a total of 104 vertebrae from T4 to
L5 were treated. Single fractures were treated in 33
operations and multiple fractures in 27 (average 2.6
vertebrae per multi-level operation; range 2–7). All
operations were performed under general anaesthesia by
surgeons with an experience of >200 KP procedures,
eliminating any relevant learning curve eﬀect.
Operative technique and ﬂuoroscopic
radiation exposure
A bilateral transpedicular approach was routinely used
for lumbar and thoracolumbar vertebrae [4]. Thoracic
vertebrae above T11 were routinely treated through an
unilateral extrapedicular approach [1, 2]. Uni- or bilat-
eral treatment of thoracolumbar vertebrae was at the
discretion of the surgeon according to vertebral size and
fracture morphology.
Simultaneous biplanar ﬂuoroscopy using separate c-
arms was used in all cases (Fig. 1a, b). All tool place-
ment steps [1, 4] were simultaneously monitored in both
ﬂuoroscopic planes. Balloon inﬂation was monitored
frequently at the discretion of the surgeon, as was
polymethylmethacrylate (PMMA) injection. Whenever
feasible with regard to the ﬂuoroscopic visualisation, the
PMMA injection of up to three adjacent vertebrae was
done simultaneously. Exposure time was recorded in
minutes separately for both c-arms via the built-in tim-
ers, beginning with patient positioning until the ﬁnal
documentation exposure. This ensured documentation
of the entire ET of a given patient from entering to
leaving the operating theatre. The surgeons controlled
the exposure via foot switches. The c-arms were oper-
ated in automatic brightness control mode, with ﬁxed
diaphragms and in non-pulsed mode. No extraordinary
eﬀort was made to reduce ET that would have jeopar-
dised the safety of the procedure.
Various c-arm ﬂuoroscopes (Siemens Siremobil
Compact, Siemens Siremobil 2000, Siemens Siremobil
Iso-C) were used during the ﬁrst 44 cases (1–44 in
Table 1) in which ET in both planes (ETap and ETlat) as
well as tube voltage (TVap and TVlat) were recorded at
the end of each operative session (Table 1). Average ETs
for single and multiple levels were calculated from these
values (Table 2). Since the projections and patient posi-
tions did not vary signiﬁcantly during operative sessions
with treatment of up to three adjacent vertebrae, it was
assumed, that the tube voltages TVap and TVlat estab-
lished by the automatic brightness control unit, remained
constant throughout the procedure. Variations of TV
between non-adjacent levels and due to the application of
contrast medium laden PMMA or the presence of tools
in the X-ray beam could not be considered.
Two c-arm ﬂuoroscopes (Siemens Siremobil Com-
pact) equipped with dose-area-product (DAP) meters
were available for the subsequent 16 cases (45–60 in
Table 1), in which DAP was recorded in both planes in
addition to ET and TV. The ap-unit was larger than the
lat-unit with a span of 79 cm (100 cm focus to image
intensiﬁer distance) versus a span of 70 cm (90 cm focus
to image intensiﬁer distance). The larger unit was used in
the ap-plane to allow greater freedom of movement
during tool manipulation. Focus to skin distances for
normal adult patients typically amounted to 46 cm in
the ap-plane and to 36 cm in the lat-plane. Entrance
ﬁeld sizes determined by means of X-ray ﬁlms were
37.4 cm2 for the ap-plane and 30.8 cm2 for the lat-plane
(Fig. 2—online supplemental material). However, as
individual patients may show a deviation from these
ﬁeld sizes due to body size and positioning, the sub-
sequent dose estimations can only be regarded as a
closer approximation.
Patient dose
The estimation of patient dose was based on the in-
traoperatively gathered radiation exposure data of
cases 45 to 60 recorded in Table 1, in which the values
of DAP were known from the direct measurement of
the DAP meters. The proper function of the DAP
meters was controlled by the Technical Inspection
Agency (TU¨V Su¨ddeutschland) by means of a cali-
brated dosemeter (PTW Diados E, calibration date
09.2003). For all ﬂuoroscopes involved, the total ﬁl-
tration amounted to 3 mm aluminium. It was decided
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Table 1 Patient and exposure
data
Case groups 1–3; 4 & 5; 10 &
48; 19 & 50; 21 & 22 & 53 res-
pectively are the same patient
treated in separate sessions and
at diﬀerent levels
AS age and sex of the patient;
VL vertebral levels treated;
NL number of levels treated;
ET ﬂuoroscopy exposure times
in ap- and lat-plane; TV tube
voltage for ap- and lat-plane;
DAP dose–area product of
ap- and lat- plane; * tube volt-
age was not recorded. Mean,
Min, Maxmean values per case,
minimum and maximum values
are presented
Case AS VL NL ETap
(min)
ETlat
(min)
TVap
(kV)
TVlat
(kV)
DAPap
(Gy·cm2)
DAPlat
(Gy·cm2)
1 BI 74 F T7,8 2 1.5 2.9 73 64
2 BI 74 F T10 1 0.9 1.6 79 77
3 BI 74 F T11 1 1.0 2.2 71 68
4 BF 90 M T8,11 2 1.5 2.4 80 65
5 BF 90 M T6,7,12 3 2.0 4.3 69 64
6 BE 72 F T12,L3 2 1.7 3.2 80 92
7 CG 83 F T12,L4 2 1.4 1.9 87 102
8 DL 79 F T7,11 2 2.4 4.8 73 64
9 DE 62 F T12,L1,L3 3 3.4 5.0 66 99
10 EV 75 F L5 1 1.4 3.3 76 80
11 EM 79 F L4 1 1.2 2.1 69 68
12 EK 65 M T6,12,L3 3 3.0 5.3 67 64
13 FC 59 F T9-12 4 3.0 4.6 88 88
14 FA 78 F L1,2 2 2.8 3.8 69 98
15 GK 55 M T12 1 3.0 2.4 85 82
16 GJ 64 M T5-11 7 5.9 8.6 79 69
17 HG 62 F L1 1 2.0 2.3 68 65
18 HL 74 M L1,3 2 2.5 5.8 74 73
19 HC 66 F L3 1 2.5 2.8 83 110
20 HF 76 F L3 1 2.3 4.3 70 40
21 IE 69 F T8 1 1.8 2.5 70 63
22 IE 69 F T6,7,11 3 5.2 6.7 63 70
23 KT 54 M T4 1 1.9 3.3 63 98
24 KG 50 M L1 1 0.9 0.9 110 99
25 KM 81 F T6,7 2 0.9 3.7 69 67
26 LA 75 F T5,7 2 2.8 3.4 70 65
27 MA 73 F T12,L1,2 3 3.7 6.2 70 73
28 MJ 74 F T11 1 1.5 2.6 69 68
29 MF 76 M L2 1 0.9 1.3 74 82
30 MM 82 F L1 1 1.7 3.2 74 98
31 NE 78 F L3 1 0.5 1.6 78 77
32 PJ 77 M L3 1 1.3 2.3 68 78
33 PT 89 F L2 1 1.4 1.9 69 80
34 SH 81 F L2 1 2.8 0.7 78 75
35 SH 69 F T12,L2 2 2.4 4.2 70 79
36 SM 71 F L1 1 0.9 1.3 70 59
37 SM 56 F L1 1 2.8 3.1 79 80
38 SM 79 F T9,11 2 3.9 3.8 74 104
39 TA 79 M L3 1 1.6 3.3 98 90
40 TE 73 M T12,L3 2 3.1 3.3 70 92
41 UF 80 F L4 1 1.2 2.8 70 89
42 WA 75 F L4 1 1.1 1.7 66 75
43 WR 71 F T11,12,L3 3 5.7 7.7 81 95
44 ZG 64 F L3 1 1.3 1.8 64 64
45 CD 74 F L4 1 1.6 2.8 76 97 13.75 24.89
46 DH 85 F L1,2 2 3.0 3.6 104 110 13.32 36.81
47 ET 83 F L1 1 2.3 3.2 79 75 9.54 20.71
48 EV 76 F T12 1 1.0 0.8 66 73 3.17 5.77
49 FH 86 M L2 1 2.0 1.9 70 89 7.59 10.89
50 FC 59 F L1-4 4 2.2 5.8 88 110 26.85 25.53
51 FK 86 F L2 1 0.5 0.6 64 69 1.49 2.61
52 HH 81 F L2 1 0.9 1.5 69 88 4.24 6.70
53 IE 69 F T9,12,L1 3 3.8 3.5 80 62 12.28 13.68
54 JM 49 F T6,7 2 1.8 4.2 68 69 6.73 22.21
55 KE 78 F L1 1 1.2 2.1 71 77 4.60 15.93
56 PA 82 M T12,L1 2 1.9 1.8 78 81 10.26 15.68
57 SB 66 M L1,2 2 1.7 4.3 85 110 17.12 28.63
58 SE 70 M L1 1 2.4 2.2 77 74 9.56 13.05
59 WH 82 M L3 1 2.8 3.0 * 89 7.37 18.68
60 WM 68 M T11,12,L5 3 2.4 1.9 93 110 10.18 17.96
Mean 73 1.7 2.1 3.2 75 81 9.88 17.48
Min 49 1 0.5 0.6 63 40 1.49 2.61
Max 90 7 5.9 8.6 110 110 26.85 36.81
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to determine ESD and E as descriptors of patient
dose.
ESD relates to the dose dependant threshold for
development of early transient and main erythema [15]
at the entrance side of the patient. E is the only available
dose descriptor related to the risk of developing radia-
tion induced cancers, which enables comparison
with patient doses acquired from diﬀerent exposure
situations, such as CT. Entrance skin dose and E were
calculated via Eqs. 1, 2, 3, 5 (see supplemental online
material) for cases 45–60 and are presented in Table 3.
ICRP 60 [7] provides ‘‘nominal probability coeﬃ-
cients’’ for developing cancers in a lifetime after a single,
acute irradiation. The coeﬃcient is 0.05 (=5%) per
Sievert (Sv)1) of E for fatal cancers; 0.01 (=1%) for
non-fatal cancers and 0.06 (=6%) for any cancer. While
these coeﬃcients principally relate to a homogenous
irradiation of the whole body, an application in the
ﬂuoroscopy setting is not ruled out. The coeﬃcients will
however be less accurate in this application. Equations
(4) and (5) allow a theoretical estimation of the increase
in lifetime risk for developing cancers after a single KP
procedure for the obtained mean and maximum E values
of cases 45–60 (Table 3).
Dosimetrical methodology
Entrance skin dose was calculated via Eq. (1). Entrance
skin dose values for both planes (ESDap, ESDlat) of
cases 45–60 are presented in Table 3.
While the use of E to describe patient exposures after
small ﬁeld size examinations, like in this study, is not
unproblematic and may even cause criticism, it has to be
seen as a makeshift as there is no other way to achieve a
patient dose risk relation in a ﬂuoroscopy application
such as KP. Ideally, E is determined from a given set of
selected organ doses through Eq. (2), incorporating so-
called tissue weighting factors, which account for the
probability of non-deterministic eﬀects (malignancies) of
speciﬁc organs after irradiation [7]. In the context of this
study, however, it was unthinkable to provide organ
dose conversion coeﬃcients to calculate organ doses
from entrance dose for all the tube voltages, projections
and vertebrae involved, to achieve E with Eq. (2). All the
more because the radiation ﬁelds were very small and the
decision, which organs were aﬀected to which degree,
was impossible to reach with the necessary precision.
Fortunately, there is an earlier empirical ﬁnding, namely
that E can be roughly estimated from DAP even without
precise knowledge of ﬁeld size and ﬁeld position with
regard to the patient with Eq. (3) [10]. This work pro-
vides conversion coeﬃcients to calculate E from DAP.
Table 2 Fluoroscopic ETs per treated level of the case groups
ETapper single
level (min)
ETlatper single
level (min)
ETapper multi-level
(min)
ETlatper multi-level
(min)
All cases 1.6 (0.5–3.0) 2.2 (0.6–4.3) 1.1 (0.5–2.0) 1.7 (0.6–2.9)
Cases 1–44 1.6 (0.5–3.0) 2.3 (0.7–4.3) 1.1 (0.5–2.0) 1.8 (1.0–2.9)
Cases 45–60 1.6 (0.8–2.5) 2.0 (0.6–3.2) 1.0 (0.6–1.5) 1.5 (0.6–2.7)
Mean exposure time in the respective plane (ETap or ETlat) in minutes of the entire collective (all), case group 1–44 and case group 45–60.
Exposure times are broken down into minutes/level for single level cases and minutes per level for multi-level cases. Minimum and
maximum values are respectively listed in brackets
Fig. 1 Drawing of the typical operative set-up for percutaneous
KP under biplanar ﬂuoroscopic guidance in a lateral view (A) and
birds eye view (B). The surgeon and assistant are positioned at the
sides of the patient, while the scrub nurse is at the foot end and the
anaesthesiologist is at the head of the table
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The only information required to select the conversion
coeﬃcients is the tube voltage, beam ﬁltration, the body
region examined (e.g. lumbar spine) and the projection
(either ap or pa/lat). Following this procedure, the E
values for each plane (Eap and Elat for cases 45 to 60
were estimated. As E, is deﬁned as an additive quantity
[7], the sum of the values of both planes (Etot = Eap +
Elat) was included in Table 3.
Although DAP was not measured amongst the ﬁrst
44 cases, disallowing the direct calculation of ESD and
E, an endeavour was made to determine the range of
patient dose in these cases in order to exclude signiﬁ-
cantly higher values than ascertained for cases 45–60. To
achieve this, the relation between the measured DAP
and corresponding ET of cases 45–60 was determined
and regression lines were established (Fig. 3). Via these,
ﬁctitious DAP-values for cases 1–44 could be deter-
mined from their ET-values (DAPap= 4.77·ETap and
DAPlat= 6.19·ETlat). The application of Eqs. (1) and
(3) subsequently allowed the determination of the range
of theoretical patient doses.
Formulas
Entrance skin dose (mGy) can easily be determined from
the measured DAP (mGy·cm2) values with:
ESD ¼ DAP
FE
 BSF ð1Þ
with FE (cm2) is the ﬁeld size in focus to skin distance
and BSF the so-called backscatter factor, which con-
siders the contribution of radiation, backscattered by the
patient, to ESD. An average value of BSF (BSF=1.2)
for all occurring tube voltages was derived from the
literature [5, 13].
E (mSv) is principally calculated from a given set of
selected organ doses HT (mSv) along:
E ¼
X
T
wT  HT ð2Þ
with wT so-called tissue weighting factors, which account
for the probability of non-deterministic eﬀects (malig-
nancies) in organ T after irradiation [7].
E is alternatively estimated along conversion coeﬃ-
cients fE (mSv·mGy)1 ·cm)2) taken from [10] from
DAP along:
E ¼ fE DAP ð3Þ
where fE is the dose conversion coeﬃcient. The fE-values
by Le Heron [10] are given in 10 kV steps of tube volt-
age, the fE-values for the actual tube voltages were at-
tained by interpolation.
The risk Rfatal for radiation induced fatal cancers is
estimated with:
Rfatal ¼ 0:05 E ð4Þ
from the eﬀective energy E (Sv) with 0.05 (Sv)1) the
nominal probability coeﬃcient taken from [7].
In an analogous way the risk for non-fatal cancers
Rnon-fatal is estimated with:
Rnonfatal ¼ 0:01 E ð5Þ
with 0.01 the nominal probability coeﬃcient from [7].
The risk of developing any cancer, fatal or non-fatal is
derived by adding the obtained Rfatal and Rnon-fatal val-
ues or by substituting 0.06 as the nominal probability
coeﬃcient in the formula.
Fig. 2 Schematic representation of the ﬂuoroscopy setting used to
experimentally determine the entrance ﬁeld sizes in both planes of
view. A typical operative set-up was simulated and X-ray ﬁlms were
exposed at the usual distance of the patient from the focus (46 cm
focus to skin distance ap and 36 cm focus to skin distance lat).
Field sizes of 37.4 cm2 in the ap plane and 30.8 cm2 in the lat plane
were determined. ap anterior–posterior ﬂuoroscopy unit with
100 cm focus to image intensiﬁer distance, lat lateral ﬂuoroscopy
unit with 90 cm focus to image intensiﬁer distance, BV image
intensiﬁer
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Results
No complications occurred during the procedures and
no procedure had to be aborted because of inadequate
ﬂuoroscopic visualisation.
Exposure time
Variations in ET were only due to technical operative
factors such as visualisation and fracture complexity.
With very few exceptions, ETlat was found to be longer
than ETap with an average of 3.2 min (range 0.6–8.6)
versus 2.1 min (range 0.5–5.9) per case (Table 1). When
broken down into ET per level, average ETlat was
2.2 min (range 0.6–4.3) per level for single fracture cases
and 1.7 min (range 0.6–2.9) per level for multiple frac-
ture cases (Table 2). ETap and consistently remained
below ETlat in this per level breakdown. Mean ET was
not found to diﬀer relevantly between the case groups 1–
44 (no direct DAP measurement) and 45–60 (direct DAP
measurement).
Patient dose
Entrance skin dose of case group 45–60 derived from
Eq. (1) was found to range from a minimum of 0.05 Gy
in the ap plane to 1.43 Gy in the lat plane (Table 3). The
average value of the lat plane was markedly higher than
for the ap plane with 0.68 versus 0.32 Gy respectively
(Table 3).
Cumulative E values of case group 45–60 (Table 3),
deduced from Eq. (3), range from 0.47 mSv to
10.14 mSv with an average of 4.28 mSv.
Using these values in Eqs. (4) and (5), the lifetime risk
of developing a cancer after a single KP procedure is
theoretically increased by 0.025% (0.02% for fatal
cancers) for the mean E value of 4.28 mSv and by 0.06%
(0.05% for fatal cancers) for the maximum E value of
10.14 mSv.
The correlation of ET and DAP of case group 45–60
in Fig. 3 reveals, that the DAP-values scatter consider-
ably along the ﬁtted regression line (as could have been
expected due to varying patient thickness) and that they
are higher for the lat-projection (larger patient diame-
ter), than for the ap-projection. Figure 3 also shows that
it is mainly the ET, which governs the DAP. Neverthe-
less, in some cases the measured DAP-value was higher
than predicted by the regression line by a factor of up to
2.7 (case 50 FC ap in Table 1 and encircled in Fig. 3).
Using the regression lines to determine DAP from ET
Table 3 Patient doses of cases
45 to 60
ESD entrance skin dose in
ap- and lat-plane, E eﬀective
dose in ap- and lat- plane and
total (ap + lat), * Eap and Etot
could not be determined in this
case as the tube voltage was not
recorded
Case ESDap(Gy) ESDlat(Gy) Eap(mSv) Elat(mSv) Etot(mSv)
45 CD 0.44 0.97 2.92 3.08 6.00
46 DH 0.43 1.43 3.75 5.14 8.90
47 ET 0.31 0.81 2.11 1.89 4.00
48 EV 0.11 0.22 0.57 0.51 1.08
49 FH 0.24 0.42 1.47 1.23 2.70
50 FC 0.86 0.99 6.57 3.57 10.14
51 FK 0.05 0.10 0.26 0.21 0.47
52 HH 0.14 0.26 0.81 0.75 1.56
53 IE 0.39 0.53 2.75 0.92 3.66
54 JM 0.22 0.87 1.26 1.79 3.05
55 KE 0.15 0.62 0.91 1.51 2.41
56 PA 0.33 0.61 2.24 1.58 3.82
57 SB 0.55 1.12 4.06 4.00 8.06
58 SE 0.31 0.51 2.06 1.17 3.23
59 WH 0.24 0.73 * 2.11 *
60 WM 0.33 0.70 2.62 2.51 5.13
Mean 0.32 0.68 2.29 2.00 4.28
Minimum 0.05 0.10 0.26 0.21 0.47
Maximum 0.86 1.43 6.57 5.14 10.14
Fig. 3 Dependence of DAP on ﬂuoroscopic ET for cases 45 to 60
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values in case group 1–44 may therefore lead to an
underestimation by a factor of 2.7 in the worst case.
Assuming that patients on the whole were comparable
between the case groups, this factor could aﬀect the
dimension of subsequently calculated ESD and E in an
occasional individual of the latter case group. This will
however not relevantly aﬀect the mean patient doses in
the whole case group, all the more so since the mean ETs
of the groups are comparable (Table 2). Mean patient
doses in the whole collective would therefore have been
rather the same as in the case group 45–60 (Table 3).
Nevertheless, it cannot be excluded, that there are
deviators hidden in the case group 1–44, which received
2–3 times higher patient doses than those in Table 3.
Since the maximum ET in a single patient (case 16 GJ in
Table 1) treated for seven levels is higher than the
average by a factor of 1.5, a four fold higher maximum
patient dose than that established in Table 3, cannot
strictly be excluded for this patient on the basis of the
data collected in this study. Therefore, assuming a worst
case E value of 40 mSv for this patient would lead to a
theoretical increase in lifetime risk for developing a
cancer by 0.24% (0.2% for fatal cancers) through
application of Eqs. (4) and (5).
Discussion
Exposure time
Simultaneous biplanar ﬂuoroscopy was used in order to
decrease radiation exposure (Fig. 1a, b). The rationale
behind this set-up is that once an optimal setting has
been found, it is maintained throughout the procedure
and no radiation is ‘‘wasted’’ during readjusting to the
second plane of view.
The ﬁnding that longer ET was almost always re-
quired in the lat view (Table 1) is due to the monitoring
of the PMMA injection which relies heavily on the lat
view for recognising even minimal epidural or paraver-
tebral venous leakage. On an average, ETlat of 2.2 min
was required in cases treated for single levels (Table 2).
When treating multiple levels, the ETlat per level was
reduced to 1.7 min per level (Table 2). This is because up
to three adjacent vertebrae can be visualised with the
same c-arm setting, occasionally allowing simultaneous
PMMA injection.
The addition of ETap and ETlat to a total ET per
treated level or case is not rational from a dosimetrical
standpoint as they relate to diﬀerent projections. Nev-
ertheless, total ET per level provides the clinician with a
rough guideline as to the amount of radiation that is
‘‘used’’ and may allow an-acknowledgeably unscientiﬁc-
comparison between diﬀerent operative set-ups and
techniques. With this restriction in mind, average total
ET per level in single fracture cases calculated from
Table 1 was 3.8 min (range 1.1–6.6 min). In multiple
level cases, the average total ET per level was 2.8 min
(range 1.1–4.5 min). Corresponding total ET per level in
multiple level VP cases (average 4.25 vertebrae per ses-
sion) by Harstall et al. [6] was slightly lower with
2.2 min. This may reﬂect the greater technical demand
of KP over VP during tool introduction and balloon
inﬂation. In the only other dosimetrical investigation of
patient exposure in KP by Perisinakis et al. [12], the
average total ET was 10.1 min (4.7 min ETap and
5.4 min ETlat) in 11 patients. Although not clearly stated
by these authors, their procedures appear to have been
conducted with a single ﬂuoroscopy unit. In this case,
the signiﬁcantly shorter ET of our collective would serve
to underline the radiation saving rationale behind
simultaneous biplanar ﬂuoroscopy.
Patient radiation dose
As the patient exposure data presented in Table 1 was
obtained in a genuine operative setting by experienced
surgeons without unrealistic eﬀorts to reduce exposure,
the derived patient doses in Table 3 may be considered
as a genuine baseline for discussing the hazards of
radiation exposure to patients during KP.
However, while ET can be measured accurately, the
patient doses derived from these values are subject to
several sources of error: (1) The experimentally deter-
mined ﬁeld sizes (Fig. 2) do not allow for individual
variations due to patient size and positioning, so that the
calculations of ESD (Table 3) from Eq. (1) have to be
regarded as the closest possible approximation assuming
average patient dimensions and exactly centred posi-
tioning. (2) The determination of E (Table 3) from a
ﬂuoroscopy application with small and varying ﬁelds of
exposure (such as in KP) as per Eq. (3) has not been
scientiﬁcally veriﬁed. The same applies for the sub-
sequent calculations of the lifetime risk for developing
cancers as per Eqs. (4) and (5). These values therefore
have to be regarded as theoretical until conﬁrmed by
further investigations.
The calculated ESD values of the patients in Table 3
show that the 2 Gy threshold to early transient erythema
[15] was not reached in either plane. Correspondingly,
no signs of erythema developed in any of the patients.
ESDap was well within the safety limit with an average of
0.23 Gy and even the maximum value only reached
0.86 Gy. ESDlat is of greater concern, as the average
value reached 0.68 Gy and the maximum value rose to
1.43 Gy. DAP is however not only related to ET, but
also reﬂects the voltage and current adjustment of the
automatic brightness control unit according to patient
thickness. Using Eq. (1) and the regression line calcu-
lation, a theoretical ETlat of 8 and 25 min respec-
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tively would be necessary for the induction of a transient
early erythema (2 Gy threshold) or main erythema
(6 Gy threshold [15]) in an average patient treated with
our operative set-up and a permanent ﬁeld of exposure.
These ﬁndings reveal our chosen operative setting to be
disadvantageous with regard to the smaller lateral
c-arm, as it almost always had the longer ET, but is
closest to the patients skin (Table 1, Fig. 2). In cases
that are diﬃcult to visualise (e.g. pre-existing scoliosis)
or that require continuous live ﬂuoroscopy during
PMMA injection due to complex pathology (e.g. pos-
terior wall disruption or osteolysis) it is conceivable that
ETlat could reach levels of concern. The use of a larger
c-arm, would hereby markedly reduce ESD, as skin
exposure drops according to an inverse second order
function with increased skin to focus distance.
Eﬀective dose values were found to reach an average
of 4.28 mSv with a maximum of 10.14 mSv in the case of
group 45–60. While higher deviations of a factor 2–4
theoretically cannot be excluded for all individuals of
case group 1–44 according to the regression line deter-
mination (Fig. 3), the comparable ET values between the
case groups (Table 2) allow a reasonable assumption of a
comparable range of patient doses between the groups.
Our mean E values are found to compare favourably
with those of Perisinakis et al. [12], which averaged 8.5–
12.7 mSv, in dependence of the treated region, in 11
patients with an average total ET of 10.1 min.
The lifetime risk of developing a cancer after a single
KP procedure is theoretically increased by 0.02% –
0.06% in case group 45–60. These values are to be seen
in relation to a baseline of 20% – 25% cause of death
from cancer in the Western European population. This
20%–25% lifetime risk of developing a fatal cancer is
therefore theoretically increased by 0.02% for the mean
E value of 4.28 mSv and by 0.05% for the maximum E
value of 10.14 mSv after a single KP procedure. In the
estimated worst case of E 40 mSv the risk would in-
crease by 0.2%. Although low, the risk of developing an
early transient erythema or a cancer cannot be totally
disregarded.
While data for comparison is lacking, it is unlikely
that comparable fractures could be treated with lesser
E-values through CT guided KP as repeated scanning
and additional ﬂuoroscopy during PMMA injection is
usually necessary. The mean value for Etot (4.28 mSv),
as reported in Table 3, is lower than E-values resulting
from common, not specially dose reduced CT-examin-
ations of the whole abdomen, with only the maximum
value (10.14 mSv) equalling the typical mean value for
abdominal CT [3]. According to the review by Perisi-
nakis et al. [12], our mean KP patient dose of 4.28 mSv
is well within the range of other common interventional
ﬂuoroscopic procedures such as radiofrequency catheter
cardiac ablation (5.7 mSv), endoscopic retrograde cho-
langiopancreatography (12.4 mSv) and enteroclysis
(14.0 mSv).
Reducing radiation exposure in KP
Exposure was directed by the surgeon via foot pedals.
As the entire ﬁnesse of the procedure is in the hands of
the surgeon, this is the only way of optimising ﬂuoros-
copy exposure without endangering the patient and
hampering the ﬂow of the operation. It is highly
doubtful, whether exposure guided by a radiology
technician would have been able to achieve comparable
values or in any way have contributed positively to the
success of the procedure.
A reduction of ET in this could have been achieved
through pulsed imaging. The concern of missing PMMA
leakage however prompted the surgeons to use non-
pulsed imaging in short bursts. Nevertheless, pulsed
imaging should be used where justiﬁable (e.g. for tool
introduction). Studies will need to be directed towards
comparing the risk of PMMA leakage in pulsed and
non-pulsed imaging before formulating recommenda-
tions in this regard.
Acknowledgements Figure 1 was provided through courtesy of
Spinegraphics.
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